J.P. Marvel Investment Advisors LLC Has $8,863,000 Position in Pfizer, Inc. (PFE)

J.P. Marvel Investment Advisors LLC decreased its stake in shares of Pfizer, Inc. (NYSE:PFE) by 4.2% during the third quarter, Holdings Channel reports. The institutional investor owned 261,684 shares of the biopharmaceutical company’s stock after selling 11,490 shares during the period. Pfizer makes up about 3.1% of J.P. Marvel Investment Advisors LLC’s holdings, making the stock its 5th largest position. J.P. Marvel Investment Advisors LLC’s holdings in Pfizer were worth $8,863,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. OLD Republic International Corp boosted its position in shares of Pfizer by 49.4% in the third quarter. OLD Republic International Corp now owns 1,538,500 shares of the biopharmaceutical company’s stock valued at $47,758,000 after buying an additional 509,000 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Pfizer by 2.9% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 2,630,762 shares of the biopharmaceutical company’s stock valued at $89,102,000 after buying an additional 73,797 shares in the last quarter. Cable Hill Partners LLC boosted its position in shares of Pfizer by 6.5% in the third quarter. Cable Hill Partners LLC now owns 5,051 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 308 shares in the last quarter. Mosaic Family Wealth LLC boosted its position in shares of Pfizer by 18.3% in the third quarter. Mosaic Family Wealth LLC now owns 51,450 shares of the biopharmaceutical company’s stock valued at $1,743,000 after buying an additional 7,963 shares in the last quarter. Finally, Covington Capital Management boosted its position in shares of Pfizer by 2.7% in the third quarter. Covington Capital Management now owns 170,195 shares of the biopharmaceutical company’s stock valued at $5,765,000 after buying an additional 4,416 shares in the last quarter. 69.53% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer, Inc. (NYSE:PFE) opened at 32.61 on Tuesday. Pfizer, Inc. has a 52 week low of $28.74 and a 52 week high of $37.39. The company has a 50 day moving average of $32.26 and a 200 day moving average of $33.03. The company has a market capitalization of $197.89 billion, a price-to-earnings ratio of 27.80 and a beta of 0.94.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $0.47 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.50 by $0.03. The business had revenue of $13.60 billion for the quarter, compared to analyst estimates of $13.64 billion. Pfizer had a return on equity of 23.18% and a net margin of 13.50%. The company’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.53 earnings per share. On average, equities analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 1st. Stockholders of record on Friday, February 3rd will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.93%. This is an increase from Pfizer’s previous quarterly dividend of $0.30. The ex-dividend date is Wednesday, February 1st. Pfizer’s dividend payout ratio is presently 110.35%.

“J.P. Marvel Investment Advisors LLC Has $8,863,000 Position in Pfizer, Inc. (PFE)” was first posted by sleekmoney and is owned by of sleekmoney. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be read at http://sleekmoney.com/j-p-marvel-investment-advisors-llc-has-8863000-position-in-pfizer-inc-pfe/1659572.html.

Several equities analysts recently commented on the stock. Vetr cut shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $35.47 price objective for the company. in a research note on Monday, February 6th. Morningstar, Inc. reissued a “buy” rating on shares of Pfizer in a research note on Thursday, February 2nd. Atlantic Securities set a $37.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, February 1st. BMO Capital Markets reissued a “market perform” rating and issued a $33.00 price target on shares of Pfizer in a research note on Monday, January 30th. Finally, Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, January 25th. Thirteen research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Pfizer presently has an average rating of “Buy” and an average price target of $37.15.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.

5 Day Chart for NYSE:PFE

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/j-p-marvel-investment-advisors-llc-has-8863000-position-in-pfizer-inc-pfe/1659572.html

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *